{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:31:28Z","timestamp":1778877088549,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66238-1","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:02:59Z","timestamp":1764669779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Microbial Product Cocktails for Personalized Cancer Immunotherapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Yue","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen E.","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-7594","authenticated-orcid":false,"given":"David J.","family":"DeGraff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-5463","authenticated-orcid":false,"given":"Joseph C.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7388-2110","authenticated-orcid":false,"given":"Pak Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"66238_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41568-023-00594-2","volume":"23","author":"G El Tekle","year":"2023","unstructured":"El Tekle, G. & Garrett, W. S. Bacteria in cancer initiation, promotion and progression. Nat. Rev. Cancer 23, 600\u2013618 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"66238_CR2","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602 (2021).","journal-title":"Science"},{"key":"66238_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"66238_CR4","first-page":"137","volume":"5","author":"W Busch","year":"1868","unstructured":"Busch, W. Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl. Klin. Wochenschr. 5, 137 (1868).","journal-title":"Berl. Klin. Wochenschr."},{"key":"66238_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0029-1196806","volume":"8","author":"F Fehleisen","year":"1882","unstructured":"Fehleisen, F. Ueber die Z\u00fcchtung der Erysipelkokken auf k\u00fcnstlichem N\u00e4hrboden und ihre \u00dcbertragbarkeit auf den Menschen. Dtsch Med Wochenschr. 8, 553\u2013554 (1882).","journal-title":"Dtsch Med Wochenschr."},{"key":"66238_CR6","first-page":"375","volume":"131","author":"WB Coley","year":"1906","unstructured":"Coley, W. B. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. Am. J. Med Sci. 131, 375\u2013430 (1906).","journal-title":"Am. J. Med Sci."},{"key":"66238_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/bbug.1.2.11248","volume":"1","author":"TA Oelschlaeger","year":"2010","unstructured":"Oelschlaeger, T. A. Bacteria as tumor therapeutics? Bioengineered bugs 1, 146\u2013147 (2010).","journal-title":"Bioengineered bugs"},{"key":"66238_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","volume":"18","author":"N Lobo","year":"2021","unstructured":"Lobo, N. et al. 100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19. Nat. Rev. Urol. 18, 611\u2013622 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"66238_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat. Rev. Urol. 11, 153\u2013162 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"66238_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"66238_CR11","doi-asserted-by":"publisher","unstructured":"Jiang, S. & Redelman-Sidi, G. BCG in Bladder Cancer Immunotherapy. Cancers (Basel) 14, https:\/\/doi.org\/10.3390\/cancers14133073 (2022).","DOI":"10.3390\/cancers14133073"},{"key":"66238_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm, D. L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124\u20131129 (2000).","journal-title":"J. Urol."},{"key":"66238_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","volume":"49","author":"JA Witjes","year":"2006","unstructured":"Witjes, J. A. Management of BCG failures in superficial bladder cancer: a review. Eur. Urol. 49, 790\u2013797 (2006).","journal-title":"Eur. Urol."},{"key":"66238_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat, A. M. et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat. Rev. Urol. 14, 244\u2013255 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"66238_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/MOU.0000000000000863","volume":"31","author":"VT Packiam","year":"2021","unstructured":"Packiam, V. T., Richards, J., Schmautz, M., Heidenreich, A. & Boorjian, S. A. The current landscape of salvage therapies for patients with bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer. Curr. Opin. Urol. 31, 178\u2013187 (2021).","journal-title":"Curr. Opin. Urol."},{"key":"66238_CR16","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","volume":"39","author":"C Lebacle","year":"2021","unstructured":"Lebacle, C., Loriot, Y. & Irani, J. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know? World J. Urol. 39, 4037\u20134046 (2021).","journal-title":"World J. Urol."},{"key":"66238_CR17","doi-asserted-by":"crossref","unstructured":"Tse, J., Singla, N., Ghandour, R., Lotan, Y. & Margulis, V. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opin Investig Drugs, 1-14 (2019).","DOI":"10.1080\/13543784.2019.1655730"},{"key":"66238_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100241","volume":"33","author":"H Pan","year":"2021","unstructured":"Pan, H., Zheng, M., Ma, A., Liu, L. & Cai, L. Cell\/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy. Adv. Mater. 33, e2100241 (2021).","journal-title":"Adv. Mater."},{"key":"66238_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal Transduct. Target Ther. 6, 291 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"66238_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"K Hou","year":"2022","unstructured":"Hou, K. et al. Microbiota in health and diseases. Signal Transduct. Target Ther. 7, 135 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"66238_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Lehar","year":"2009","unstructured":"Lehar, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659\u2013666 (2009).","journal-title":"Nat. Biotechnol."},{"key":"66238_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.14309\/ajg.0000000000002167","volume":"118","author":"AS Gulati","year":"2023","unstructured":"Gulati, A. S., Nicholson, M. R., Khoruts, A. & Kahn, S. A. Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation. Am. J. Gastroenterol. 118, 435\u2013439 (2023).","journal-title":"Am. J. Gastroenterol."},{"key":"66238_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard, C. et al. Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br. J. Cancer 125, 927\u2013938 (2021).","journal-title":"Br. J. Cancer"},{"key":"66238_CR24","doi-asserted-by":"publisher","unstructured":"Chang, T. G. et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat.Cancer https:\/\/doi.org\/10.1038\/s43018-024-00772-7 (2024).","DOI":"10.1038\/s43018-024-00772-7"},{"key":"66238_CR25","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1073\/pnas.0800823105","volume":"105","author":"PK Wong","year":"2008","unstructured":"Wong, P. K. et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. P Natl Acad. Sci. USA 105, 5105\u20135110 (2008).","journal-title":"P Natl Acad. Sci. USA"},{"key":"66238_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaz3023","volume":"367","author":"D Ho","year":"2020","unstructured":"Ho, D. Artificial intelligence in cancer therapy. Science 367, 982\u2013983 (2020).","journal-title":"Science"},{"key":"66238_CR27","doi-asserted-by":"publisher","first-page":"18627","DOI":"10.1073\/pnas.2004421117","volume":"117","author":"AC Antonelli","year":"2020","unstructured":"Antonelli, A. C., Binyamin, A., Hohl, T. M., Glickman, M. S. & Redelman-Sidi, G. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling. Proc. Natl Acad. Sci. USA 117, 18627\u201318637 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"66238_CR28","doi-asserted-by":"publisher","unstructured":"Moreo, E. et al. Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. J. Immunother.Cancer 10, https:\/\/doi.org\/10.1136\/jitc-2021-004325 (2022).","DOI":"10.1136\/jitc-2021-004325"},{"key":"66238_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fcimb.2020.00231","volume":"10","author":"S Pierce","year":"2020","unstructured":"Pierce, S., Geanes, E. S. & Bradley, T. Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response. Front Cell Infect. Microbiol 10, 231 (2020).","journal-title":"Front Cell Infect. Microbiol"},{"key":"66238_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/imt.11.102","volume":"3","author":"A Malhotra","year":"2011","unstructured":"Malhotra, A. & Shanker, A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 3, 1143\u20131166 (2011).","journal-title":"Immunotherapy"},{"key":"66238_CR31","doi-asserted-by":"publisher","first-page":"36492","DOI":"10.18632\/oncotarget.26362","volume":"9","author":"N Mukherjee","year":"2018","unstructured":"Mukherjee, N. et al. Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer. Oncotarget 9, 36492\u201336502 (2018).","journal-title":"Oncotarget"},{"key":"66238_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-0716-0327-7_19","volume":"2120","author":"D Aran","year":"2020","unstructured":"Aran, D. Cell-Type Enrichment Analysis of Bulk Transcriptomes Using xCell. Methods Mol. Biol. 2120, 263\u2013276 (2020).","journal-title":"Methods Mol. Biol."},{"key":"66238_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"66238_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong, C. Cytokine Regulation and Function in T Cells. Annu Rev. Immunol. 39, 51\u201376 (2021).","journal-title":"Annu Rev. Immunol."},{"key":"66238_CR35","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Cytokines: From Clinical Significance to Quantification. Adv. Sci. (Weinh.) 8, e2004433 (2021).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"66238_CR36","doi-asserted-by":"publisher","unstructured":"Wu, T. Z. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation-Amsterdam 2, https:\/\/doi.org\/10.1016\/j.xinn.2021.100141 (2021).","DOI":"10.1016\/j.xinn.2021.100141"},{"key":"66238_CR37","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1002\/adma.201502814","volume":"27","author":"S Wang","year":"2015","unstructured":"Wang, S., Riahi, R., Li, N., Zhang, D. D. & Wong, P. K. Single Cell Nanobiosensors for Dynamic Gene Expression Profiling in Native Tissue Microenvironments. Adv. Mater. 27, 6034\u20136038 (2015).","journal-title":"Adv. Mater."},{"key":"66238_CR38","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1021\/nn500107g","volume":"8","author":"R Riahi","year":"2014","unstructured":"Riahi, R. et al. Mapping photothermally induced gene expression in living cells and tissues by nanorod-locked nucleic acid complexes. ACS Nano 8, 3597\u20133605 (2014).","journal-title":"ACS Nano"},{"key":"66238_CR39","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell 181, 1612\u20131625 e1613 (2020).","journal-title":"Cell"},{"key":"66238_CR40","doi-asserted-by":"publisher","first-page":"8768","DOI":"10.1021\/acs.analchem.0c00057","volume":"92","author":"P Torab","year":"2020","unstructured":"Torab, P. et al. Three-Dimensional Microtumors for Probing Heterogeneity of Invasive Bladder Cancer. Anal. Chem. 92, 8768\u20138775 (2020).","journal-title":"Anal. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66238-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:03:00Z","timestamp":1764669780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66238-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66238"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66238-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10625"}}